ANCA and predicting relapse in systemic vasculitis

QJM

Volumn 88, Issue 2, 1995, Pages 127-133

  Jayne, D R W ^a   Gaskin, G ^b   Pusey, C D ^b   Lockwood, C M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; GRANULOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SEROLOGY; SYSTEMIC DISEASE; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMAN; IMMUNOGLOBULIN G; MALE; MIDDLE AGE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SUPPORT, NON-U.S. GOV'T; VASCULITIS;

EID: 0028821552     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/oxfordjournals.qjmed.a069033     Document Type: Article

References (36)

1. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85
2. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978; 89:660-78
3. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32:45-53
4. Neild CH. Infectious complications in the management of systemic vasculitis and rapidly progressive glomerulonephritis. APMIS 1991; 98 (Suppl 19):56-60
5. Cross WL, Csernok E, Flesch BK. Classic anti-neutrophil cytoplasm autoantibodies (cANCA), Wegener's autoantigen and their pathogenetic role in Wegener's granulomatosis. J Autoimmunity 1993; 6:171 -84
6. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; in press
7. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes; tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; Vol i:425-9
8. Ludemann C, Gross WL. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol 1987; 69:350-7
9. Nolle B, Specks U, Ludemann J, Rohrbach MS, Deremee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's Granulomatosis. Ann Intern Med 1989; 111:28-40
10. Savage COS, Winearls CG, Jones S, Marshall PD, Lockwood CM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 1987; Vol i:l389—93
11. Cohen Tervaert JW, Van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149:2461-5
12. Cohen Tervaert JW, Huitema MG, Hené RJ, etal. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; Vol ii:709—11
13. Gaskin G, Savage COS, Ryan JJ, Jones S, Rees AJ, Lockwood CM. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6:689-94
14. Halma C, Daha MR, Schrama E, Hermans J, Van Es LA, van der Woude FJ. Value of anti-neutrophil cytoplasmic autoantibodies and other laboratory parameters in follow-up of vasculitis. Scan J Rheumatol 1990; 19:393-7
15. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113:656-63
16. Petersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis. Clin Nephrol 1992; 37:219-28
17. Kerr GS, Fleischer TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365-71
18. Hind CRK, Winearls CG, Pepys MB. Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. EurJClin Invest 1985; 15:89-94
19. Rasmussen N, Wiik A, Hoier-Madsen M, Borregaard N, van der Woude F. Anti-neutrophil cytoplasm antibodies 1988. Lancet 1988; Vol i:706-7
20. Lockwood CM, Bates D, Jones SJ, Whitaker KB, Moss DW, Savage COS. Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis. Lancet 1987; Vol i:716—20
21. Esnault VLM, Jayne DRW, Keogan MT, etal. Anti-neutrophil cytoplasm antibodies in patients with monoclonal gammopathies. J Clin Lab Immunol 1990; 32:153-9
22. Hagen EC, Andrassy K, Csernok E, Daha MD, Gaskin G, Gross W, Lesavre P, Ludemann J, Pusey CD, Rasmussen N, Savage COS, Sinico A, Wiik A, van der Woude FJ. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. (A report on the first phase of an international cooperative study on the standardisation of ANCA assays.) J Immunol Meth 1993; 159:1 -16
23. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 1988; 82:1963-73
24. Esnault VLM, Jayne DRW, Weetman AP, Lockwood CM. IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. Immunology 1991; 74:714-18
25. Jayne DRW, Heaton A, Evans DB, Lockwood CM. Sequential ANCA and C-reactive protein estimations in the management of systemic vasculitis. APMIS 1990; 98(Suppl 19):44
26. Deremee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?. Arthritis Rheum 1989; 31:1068-73
27. Jayne DRW, Black CM, Davies M, Fox C, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137-9
28. Lockwood CM, Thiru S, Isaacs J, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341:1620-2
29. Frampton G, Jayne DRW, Lockwood CM, Cameron JS. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 1990; 82:227-32
30. Grau GE, Roux-Lombard P, Gysler C, et al. Serum cytokine changes in systemic vasculitis. Immunology 1989; 68:196-8
31. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum 1992; 35:1088-96
32. Chan TM, Frampton G, Jayne DRW, Perry GS, Lockwood CM, Cameron JS. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longditudinal study comparing anti-endothelial cell antibodies to anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993; 20:387-92
33. Qasim FJ, Thiru S, Sendo F, Oliveira DBG. The effects of antibodies against neutrophils on experimental vasculitis. Clin Exp Immunol 1993; 93(Suppl 1):22 (abstract)
34. ter Borg EJ, Horst G, Hummel E, Limburg PC, Kallenberg CG. Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B-cell activation. Clin Immunol Immunopathol 1991; 59:117-28
35. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991; 18:1298-306
36. Hays WM. The algebra of expectations. In: Statistics. New York, CBS College publishing, Holt Rhinehart Winston, 1981:630